Monitoring FTD in the peripheral blood mononuclear cells of elderly patients with metastatic colorectal cancer administered FTD plus bevacizumab as first‐line treatment-Reference-Cited by-同舟云学术

Monitoring FTD in the peripheral blood mononuclear cells of elderly patients with metastatic colorectal cancer administered FTD plus bevacizumab as first‐line treatment

Published:2021-05-03 Issue:6 Volume:112 Page:2436-2441
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Fujimoto Yoshiaki¹,Oki Eiji¹^ORCID,Qiu Shichao¹²,Nakanishi Ryota¹,Makiyama Akitaka³⁴,Miyamoto Yuji⁵,Kotaka Masahito⁶,Shimokawa Mototsugu⁷,Ando Koji¹,Kimura Yasue¹,Kitao Hiroyuki²^ORCID,Maehara Yoshihiko⁸,Mori Masaki¹

Affiliation:

1. Department of Surgery and Sciences Graduate School of Medical Sciences Kyushu University Fukuoka Japan

2. Department of Molecular Cancer Biology Graduate School of Pharmaceutical Sciences Kyushu University Fukuoka Japan

3. Department of Hematology/Oncology Japan Community Healthcare Organization Kyushu Hospital Kitakyushu Japan

4. Cancer Center Gifu University Hospital Gifu Japan

5. Department of Gastroenterological Surgery Graduate School of Medical Science Kumamoto University Kumamoto Japan

6. Gastrointestinal Center Sano Hospital Kobe Japan

7. Department of Biostatistics Graduate School of Medicine Yamaguchi University Yamaguchi Japan

8. Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers Fukuoka Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14904

Reference23 articles.

1. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

2. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

3. Potentiation of the antitumor activity of alpha, alpha, alpha‐trifluorothymidine by the co‐administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo;Emura T;Int J Oncol,2005

4. New Challenges and Inspired Answers for Anticancer Drug Discovery and Development

5. An optimal dosing schedule for a novel combination antimetabolite, TAS‐102, based on its intracellular metabolism and its incorporation into DNA;Emura T;Int J Mol Med,2004

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii;International Journal of Clinical Oncology;2023-03-24